Faculty Appointments
Patient Care Settings
Cancer, Hospital Medicine, Hematology & Oncology
Credentials
Specialties
- Medical Oncology - American Board of Internal Medicine
Education
Post-doctoral Training & Residency
07/01/2006 - 06/30/2010
Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center
07/01/2005 - 06/30/2006
Residency in Internal Medicine at New York Presbyterian Hospital/Weill Cornell
06/14/2004 - 06/30/2005
Internship in Internal Medicine at New York Presbyterian Hospital/Weill Cornell
07/01/2003 - 06/30/2004
Internship in Pathology at National Cancer Institute/National Institute of Health
VIEW ALL expand_more
Awards
2016 - Present
Young Investigator Award
Sponsor: Southwest Oncology Group (SWOG)
2010 - 2013
Wilmot Cancer Research Fellowship
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY
2009 - 2010
Young Investigator Award
Sponsor: ASCO Cancer Foundation
2007 - 2009
Clinical Scholars Biomedical Research Fellowship
Sponsor: Memorial Sloan-Kettering Cancer Center
2003 - 2004
National Institutes of Health General Research Loan Repayment Program
Sponsor: NIH
2002 - 2003
Howard Hughes Medical Institute Research Training Fellowship for Medical Students
Sponsor: Hughes
2000 - 2002
NIH Research Scholar, Cloister Program
Sponsor: Hughes
1998
Medical Student Teaching Fellowship. Dept. of Physiology
Sponsor: University of Wisconsin School of Medicine
Location: Madison, WI
VIEW ALL expand_more
Clinical Trials
A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Lead Researcher: Kristen M O'Dwyer
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
View Study Details
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Lead Researcher: Kristen M O'Dwyer
This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
View Study Details
A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Lead Researcher: Kristen M O'Dwyer
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
View Study Details
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease,A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Lead Researcher: Kristen M O'Dwyer
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
View Study Details
Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA) with Acute Lymphoclastic Leukemia (ALL)
Lead Researcher: Kristen M O'Dwyer
We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL):
"Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy.
View Study Details
Publications
Journal Articles
9/29/2016
Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. "Evolution of acute myelogenous leukemia stem cell properties after treatment and progression." Blood.. 2016 Sep 29; 128(13):1671-8. Epub 2016 Jul 15.
9/1/2016
Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R. "Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs." Bioorganic & medicinal chemistry.. 2016 Sep 1; 24(17):3876-3886. Epub 2016 Jun 16.
2/20/2016
O'Dwyer KM, Advani AS. "When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Feb 20; 34(6):533-8. Epub 2015 Dec 23.
VIEW ALL PUBLICATIONS